Relevant bibliographies by topics / Varenicline α4β2 partial agonist tobacco smoking quit

Contents

  1. Journal articles

Academic literature on the topic 'Varenicline α4β2 partial agonist tobacco smoking quit'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Varenicline α4β2 partial agonist tobacco smoking quit.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Varenicline α4β2 partial agonist tobacco smoking quit"

1

Tonstad, Serena, and Charl Els. "Varenicline: Smoking Cessation in Patients with Medical and Psychiatric Comorbidity." Clinical Medicine Insights: Therapeutics 2 (January 2010): CMT.S4012. http://dx.doi.org/10.4137/cmt.s4012.

Full text
Abstract:
Smoking remains a major public health challenge. Nicotine is the main psychoactive drug responsible for the addictive nature of tobacco, explaining why many smokers fail to quit without assistance. Pharmacotherapy for smoking cessation is deemed effective for a broad range of populations and should be routinely offered to smokers interested in making a quit attempt. Varenicline, a partial agonist at the α4β2 nicotinic receptor increases chances of quitting three-fold compared to placebo in smokers without comorbidities, and in smokers with cardiovascular disease or chronic obstructive pulmonar
APA, Harvard, Vancouver, ISO, and other styles
2

Mazur, Rafał, Sebastian Masternak, Michał Pająk, Nikodem Skoczeń, Ewelina Soroka, and Marcin Olajossy. "Can the use of varenicline improve the efficacy of pharmacotherapy for nicotine addiction?" Current Problems of Psychiatry 20, no. 1 (2019): 21–34. http://dx.doi.org/10.2478/cpp-2019-0002.

Full text
Abstract:
Abstract Introduction: Smoking is a huge medical and social problem in Poland, with as many as about 24% of Poles being addicted to nicotine. Approximately 6 million people worldwide die every year from conditions that are closely related to tobacco addiction, such as cancer and cardiovascular, metabolic or lung diseases. The difficulty in combatting nicotine dependence is largely due to the complex mechanism of this addiction. The motivation of a patient to quit smoking is of great importance in the difficult withdrawal process. Strengthening this motivation is one of the most important tasks
APA, Harvard, Vancouver, ISO, and other styles
3

McCaul, Mary E., Gary S. Wand, Hiroto Kuwabara, Robert F. Dannals, Dean Wong та Xiaoqiang Xu. "The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans". Nicotine & Tobacco Research 22, № 6 (2019): 892–99. http://dx.doi.org/10.1093/ntr/ntz080.

Full text
Abstract:
Abstract Introduction Cigarette smoking continues to be one of the most important behavioral causes of morbidity and mortality in the world. Varenicline, an α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist, has been shown to increase smoking quit rates compared with nicotine-based products. This human laboratory, double-blind, placebo-controlled study examined varenicline and placebo effects on α4β2-nAChRs occupancy, nicotine-induced change in [11C]raclopride non-displaceable binding potential (BPND), and behavioral measures of cigarette smoking, nicotine craving, and withdrawal.
APA, Harvard, Vancouver, ISO, and other styles
4

Fraile-Martínez, Óscar, Cielo García-Montero, Miguel A. Ortega, et al. "Cytisinicline vs. Varenicline in Tobacco Addiction: A Literature Review Focused on Emotional Regulation, Psychological Symptoms, and Mental Health." Healthcare 13, no. 15 (2025): 1783. https://doi.org/10.3390/healthcare13151783.

Full text
Abstract:
Tobacco use disorder remains a leading cause of preventable mortality, with nicotine playing a central role in the development and maintenance of dependence, mainly through its action on α4β2 nicotinic acetylcholine receptors (nAChRs). Smoking cessation treatments must address both physiological withdrawal and the affective disturbances (such as anxiety, irritability, and mood lability) which often facilitate relapses. This review compares two pharmacotherapies used in smoking cessation, varenicline and cytisinicline (cytisine), with particular focus on their impact on emotional regulation, ps
APA, Harvard, Vancouver, ISO, and other styles
5

Pusukuri, Sphurti, Mamatha Bellamkonda, Vishnu Vardhan Mavillapalli, and Rajendra Kumar Katte. "Comparison between the role of bupropion and varenicline in the management of nicotine dependence: A prospective comparative study." Telangana Journal of Psychiatry 11, no. 1 (2025): 41–46. https://doi.org/10.4103/tjp.tjp_16_25.

Full text
Abstract:
Introduction: Smoking is a leading preventable cause of morbidity and mortality worldwide, linked to diseases such as lung cancer, cardiovascular disorders, and chronic obstructive pulmonary disease. Despite awareness of its harmful effects, smoking cessation remains challenging due to nicotine addiction. According to the Global Adult Tobacco Survey-2, India has 266.8 million tobacco users aged 15 years or older. This study compares the effectiveness of bupropion (BUP) and varenicline (VAR) in tobacco cessation, focusing on abstinence rates and reduction in dependence levels. Materials and Met
APA, Harvard, Vancouver, ISO, and other styles
6

Driva, Stamatina, Aliki Korkontzelou, Serena Tonstad, et al. "Metabolic Changes Following Smoking Cessation in Patients with Type 2 Diabetes Mellitus." Biomedicines 12, no. 8 (2024): 1882. http://dx.doi.org/10.3390/biomedicines12081882.

Full text
Abstract:
Background: Smoking cessation is crucial for reducing complications of type 2 diabetes mellitus (T2DM), but associated weight gain can worsen glycemic control, discouraging quitting attempts. Varenicline, a partial agonist of α4β2 nicotinic receptors, aids smoking cessation. This study examines the effects of varenicline on body weight and metabolic parameters in patients with T2DM and prediabetes. Methods: Fifty-three patients were enrolled, of which 32 successfully quit smoking after a three-month course of varenicline and were examined after an additional month with no medication. Measureme
APA, Harvard, Vancouver, ISO, and other styles
7

Purvis, Tara L., Scott E. Mambourg, Tracie M. Balvanz, Heather E. Magallon, and Richard H. Pham. "Safety and Effectiveness of Varenicline in a Veteran Population with a High Prevalence of Mental Illness." Annals of Pharmacotherapy 43, no. 5 (2009): 862–67. http://dx.doi.org/10.1345/aph.1l661.

Full text
Abstract:
Background Varenicline is a selective nicotinic receptor partial agonist used to aid in the process of smoking cessation. Research on varenicline's approval for marketing demonstrated that after 12 weeks of treatment, at least 44% of patients successfully quit smoking and, on average, 13% of individuals discontinued therapy due to an adverse drug event (ADE). Growing postmarketing data linked varenicline to an increase in neuropsychiatric symptoms. Objective To evaluate the safety profile, specifically psychiatric symptoms, and effectiveness of varenicline in a veteran population and to determ
APA, Harvard, Vancouver, ISO, and other styles
8

Rana, Harshraj *. Dr. Pragnesh Patani. "RECENT ADVANCED NICOTINE DRUG DELIVERY SYSTEM AND NICOTINE ABUSE." Journal of Pharma Research 8, no. 8 (2019): 564–71. https://doi.org/10.5281/zenodo.3374089.

Full text
Abstract:
<strong><em>ABSTRACT</em></strong> <strong><em>W</em></strong><em>hile the proportion of the adult population that smokes has declined steadily in several westernized societies, the rate of successful quit attempts is still low. This is because smokers develop nicotine dependence, a powerful addiction that may require multiple attempts and long-term treatment to achieve enduring abstinence. Currently available first-line agents for smoking cessation therapy include nicotine replacement therapy (available in several formulations, including transdermal patch, gum, nasal spray, inhaler, and lozen
APA, Harvard, Vancouver, ISO, and other styles
9

Bernat, Piotr, Patrycjusz Kołodziejczyk, Jarogniew J. Łuszczki, Mirosław Zagaja, and Piotr Tutka. "Interaction of Varenicline with Classic Antiseizure Medications in the Mouse Maximal Electroshock-Induced Seizure Model." International Journal of Molecular Sciences 24, no. 3 (2023): 2616. http://dx.doi.org/10.3390/ijms24032616.

Full text
Abstract:
Varenicline (VAR) is a partial agonist of brain α4β2 nicotinic acetylcholine receptors recommended as a first line pharmacotherapy for smoking cessation. The aim of this study was to examine whether VAR affects the protective activity of four classic antiseizure medications, i.e., carbamazepine (CBZ), phenobarbital (PB), phenytoin (PHT), and valproate (VPA) on maximal electroshock (MES)-induced seizures, which may serve as an experimental model of human-generalized tonic-clonic seizures in mice. VAR administered intraperitoneally (i.p.) at a subthreshold dose of 0.5 mg/kg decreased the protect
APA, Harvard, Vancouver, ISO, and other styles
10

Robson, Noorzurani. "Varenicline – a new pharmacotherapy for smoking cessation in primary care practice." Scopus, January 1, 2010. https://doi.org/10.5281/zenodo.811474.

Full text
Abstract:
Background: Cigarette smoking causes significant morbidity and mortality and is a major public health concern worldwide. Primary care doctors are in a unique position that enables them to promote smoking cessation, as smokers are more aware of their health at the time of their clinic visit. It is thus important to offer effective treatment to help smokers stop smoking. Methods: A search of PubMed was done up to 16 December 2009, using the keywords "varenicline" alone, "varenicline" and "family medicine", and "varenicline" and "primary care". The search produced 426 articles on varenicline. The
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography